Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Aug 8;166(2):613–622. doi: 10.1007/s10549-017-4421-3

Table 1.

Distribution of clinico-pathological features of 2,653 incident invasive breast tumors by Ki67 positivity, Nurses’ Health Study, 1976–2006

Ki67 <14% n=1954 (%) Ki67 ≥14% n=699 (%) p valuea
Age at diagnosis 58.9 (8.9) 60.7 (9.4) <0.0001
Tumor size (cm) 0.0007
 < 2.0 1250 (67) 384 (58)
 2.1–4.0 459 (25) 222 (33)
 4.0+ 160 (9) 61 (9)
Tumor grade <0.0001
 Well differentiated 403 (22) 86 (13)
 Moderately differentiated 963 (51) 282 (42)
 Poorly differentiated 508 (27) 310 (46)
Lymph node involvement 0.21
 No nodes involved 1218 (67) 405 (64)
 1–3 nodes 361 (20) 146 (23)
 4–9 nodes 146 (8) 47 (7)
 10+ nodes 89 (5) 38 (6)
Tumor stage at diagnosis 0.004
 Stage 1 1073 (55) 324 (46)
 Stage 2 607 (31) 272 (39)
 Stage 3 274 (14) 103 (15)
ER status <0.0001
 ER+ 1603 (82) 449 (64)
 ER− 342 (18) 249 (36)
PR status <0.0001
 PR+ 1405 (72) 380 (55)
 PR− 541 (28) 316 (45)
Joint ER/PR status <0.0001
 ER+/PR+ 1376 (71) 363 (52)
 ER+/PR− 225 (12) 85 (12)
 ER−/PR+ 27 (1) 17 (2)
 ER−/PR− 315 (16) 231 (33)
HER2 status <0.0001
 HER2+ 360 (19) 196 (28)
 HER2− 1565 (81) 493 (72)
EGFR status <0.0001
 EGFR+ 288 (15) 250 (37)
 EGFR− 1624 (85) 427 (63)
CK5/6 status <0.0001
 CK5/6+ 172 (9) 145 (21)
 CK5/6− 1745 (91) 545 (79)
Surgery 0.12
 No 3 (0) 2 (0)
 Lumpectomy 642 (34) 247 (37)
 Mastectomy 1235 (66) 412 (62)
 Unknown type of surgery 1 (0) 1 (0)
Radiation 0.24
 Yes 833 (55) 321 (58)
 No 674 (45) 231 (42)
Chemotherapy <0.0001
 Yes 681 (45) 324 (58)
 No 845 (55) 234 (42)
Tamoxifen 0.01
 Yes 1139 (76) 371 (70)
 No 360 (24) 157 (30)

Numbers may not add to column totals due to missing data and percentages may not add to 100 due to rounding

a

χ2 tests for all variables except Kruskal-Wallis test for age at diagnosis; p-trend for categorical variables with more than two categories